Weekly round-up: Innovation takes the stage at Anglonordic Life Science Conference
Novo Holdings posts record total income and investment returns of DKK 60 billion (€8.0 billion) in 2024
Novo Holdings announced its financial results for 2024, with record returns from its Investment Portfolio and growth of the Novo Group companies driving Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of 18.0%, compared with 9.4% in 2023. Including Special Investments, the Total Investment Return for 2024 is 19.2%.
Domain Therapeutics to present data on its GPCR lead programs at AACR Annual Meeting 2025
Domain Therapeutics announces that it will be presenting new preclinical and clinical data on its key oncology programs – DT-7012, and DT-9081, alongside preclinical findings on its PAR2 biased negative allosteric modulator (NAM) program – at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, taking place in Chicago, US from 25-30 April 2025. Domain’s research demonstrates the potential of GPCRs to modulate the tumour microenvironment and enhance anti-tumour immunity.
🤝 Anglonordic Life Science Conference
What a fantastic day we had at the 21st edition of the Anglonordic Life Science Conference yesterday!
It was wonderful to see so many of our fantastic clients and industry peers at the event and to see attendees enjoy the panels and pitch sessions. These discussions are a continual reminder of the innovative and inspiring industry we work in.
A special shout out to our clients Colleen Acosta of Freya Biosciences on the Women’s Health panel, as well as Astraveus, Curve Therapeutics, Synklino, Infinitopes, Outrun Therapeutics, Resolution Therapeutics, VesperBio, Bluecell Therapeutics and ReNewVax for participating in the pitch presentations.
Thank you to M Ventures and BioPartner for co-organising the day, the countdown to next year is on!
📺 Optimum TV
In the first of our Optimum Dealmakers series, where we talk to the movers and shakers in life science investment, Optimum TV interviews Roel Bulthuis, who heads the investment team at LSE-listed investment trust Syncona. Roel outlines the importance of taking a long-term view that isn’t knocked off course by bouts of market turbulence, and how finding the right people is an “underestimated” part of building successful companies.
👥 Sector Moves
Keep up to date with the latest industry moves here.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
